Repository logo
  • English
  • Srpski (lat)
  • Српски
Log In
Have you forgotten your password?
  1. Home
  2. Browse by Author

Browsing by Author "Rasmussen, Line D (35316497000)"

Filter results by typing the first few letters
Now showing 1 - 1 of 1
  • Results Per Page
  • Sort Options
  • Loading...
    Thumbnail Image
    Some of the metrics are blocked by your 
    consent settings
    Publication
    Clinical Outcomes in Persons Coinfected with Human Immunodeficiency Virus and Hepatitis C Virus: Impact of Hepatitis C Virus Treatment
    (2020)
    Mocroft, Amanda (7006513758)
    ;
    Lundgren, Jens (35307337700)
    ;
    Gerstoft, Jan (7005184715)
    ;
    Rasmussen, Line D (35316497000)
    ;
    Bhagani, Sanjay (8203699300)
    ;
    Aho, Inka (36436796700)
    ;
    Pradier, Christian (57208854241)
    ;
    Bogner, Johannes R (7005719945)
    ;
    Mussini, Christina (7006842875)
    ;
    Uberti Foppa, Caterina (7004830366)
    ;
    Maltez, Fernando (6602422083)
    ;
    Laguno, Montse (35780408100)
    ;
    Wandeler, Gilles (24175415100)
    ;
    Falconer, Karolin (24278383500)
    ;
    Trofimova, Tatyana (59060501200)
    ;
    Borodulina, Elena (6603123975)
    ;
    Jevtovic, Djordje (55410443900)
    ;
    Bakowska, Elzbieta (6506711431)
    ;
    Kase, Kerstin (57216676281)
    ;
    Kyselyova, Galina (56817102800)
    ;
    Haubrich, Richard (57210200091)
    ;
    Rockstroh, Jürgen K (57207907471)
    ;
    Peters, Lars (15058026800)
    ;
    Losso, M. (56785746500)
    ;
    Schmied, B. (25621923500)
    ;
    Karpov, I. (15832060600)
    ;
    Clumeck, N. (55666222200)
    ;
    Hadziosmanovic, V. (59832066000)
    ;
    Begovac, J. (7004168039)
    ;
    Machala, L. (6602134360)
    ;
    Zilmer, K. (6603989068)
    ;
    Viard, J.-P. (7006656190)
    ;
    Chkhartishvili, N. (25227423400)
    ;
    Sambatakou, H. (57201621059)
    ;
    Szlávik, J. (6602551338)
    ;
    Gottfredsson, M. (57219095311)
    ;
    Mulcahy, F. (7005651577)
    ;
    Tau, L. (36573068100)
    ;
    D'Arminio Monforte, A. (7006907326)
    ;
    Rozentale, B. (8864942800)
    ;
    Uzdaviniene, V. (56884779800)
    ;
    Staub, T. (56992899600)
    ;
    Reiss, P. (55864802000)
    ;
    Reikvam, D.H. (35176496200)
    ;
    Knysz, B. (57216330515)
    ;
    Caldeira, L. (6602208012)
    ;
    Radoi, R. (56884532300)
    ;
    Panteleev, A. (56817093100)
    ;
    Dragovic, G. (23396934400)
    ;
    Tomazic, J. (6603749556)
    ;
    Miró, J.M. (57215499114)
    ;
    Scherrer, A. (35308020900)
    ;
    Gazzard, B. (57197156497)
    Background: A hepatitis C (HCV) cure is associated with changes in lipids and inflammatory biomarkers, but its impact on clinical endpoints among treated human immunodeficiency virus (HIV)/HCV coinfected persons is unclear. Methods: People living with HIV from EuroSIDA with a known HCV status after January 2001 were classified into strata based on time-updated HCV RNA measurements and HCV treatment, as either HCV antibody-negative; spontaneously resolved HCV; chronic, untreated HCV; cured HCV (HCV RNA-negative); or HCV treatment failures (HCV RNA-positive). Poisson regression was used to compare incidence rates between HCV groups for end-stage liver disease (ESLD; including hepatocellular carcinoma [HCC]), non-acquired immunodeficiency virus defining malignancy (NADM; excluding HCC), and cardiovascular disease (CVD). Results: There were 16 618 persons included (median follow-up 8.3 years, interquartile range 3.1-13.7). There were 887 CVD, 902 NADM, and 436 ESLD events; crude incidence rates/1000 person-years follow-up were 6.4 (95% confidence interval [CI] 6.0-6.9) for CVD, 6.5 (95% CI 6.1-6.9) for NADM, and 3.1 (95% CI 2.8-3.4) for ESLD. After adjustment, there were no differences in incidence rates of NADM or CVD across the 5 groups. HCV-negative individuals (adjusted incidence rate ratio [aIRR] 0.22, 95% CI 0.14-0.34) and those with spontaneous clearance (aIRR 0.61, 95% CI 0.36-1.02) had reduced rates of ESLD compared to cured individuals. Persons with chronic, untreated HCV infections (aIRR 1.47, 95% CI 1.02-2.13) or treatment failure (aIRR 1.80, 95% CI 1.22-2.66) had significantly raised rates of ESLD, compared to those who were cured. Conclusions: Incidences of NADM or CVD were independent of HCV group, whereas those cured had substantially lower incidences of ESLD, underlining he importance of successful HCV treatment for reducing ESLD. © 2019 The Author(s) 2019. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved.

Built with DSpace-CRIS software - Extension maintained and optimized by 4Science

  • Privacy policy
  • End User Agreement
  • Send Feedback